CLINICAL_TRIALS
trial_result
· 2018-11-07
Clinical Trial Update: Anlotinib in Treatment of Recurrent Small Cell Lung Cancer [Phase 2]
Summary
Phase 2 clinical trial update evaluating anlotinib for recurrent small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Peking University Cancer Hospital & Institute | Conditions: Recurrent Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN